GRC 15300

Drug Profile

GRC 15300

Alternative Names: GRC 17173; GRC15300; SAR 292833

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Glenmark Pharmaceuticals Ltd
  • Developer Glenmark Pharmaceuticals Ltd; Sanofi
  • Class Analgesics
  • Mechanism of Action TRPV3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Musculoskeletal pain; Neuropathic pain; Skin disorders; Urinary incontinence

Most Recent Events

  • 31 May 2013 Sanofi completes the phase II Alchemilla trial in Neuropathic pain in USA, Czech Republic, Hungary, Poland, Russia, Slovakia & Ukraine (NCT01463397)
  • 05 Mar 2012 Phase-II clinical trials in Neuropathic pain in Czech Republic (PO)
  • 05 Mar 2012 Phase-II clinical trials in Neuropathic pain in Hungary (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top